Midazolam (MDZ) is used for sedation in surgical procedures; its clinical effect is related to
its receptor affinity and the dose administered. Therefore, a pharmacokinetic …

Background Oral midazolam is widely used for preoperative sedation in children. We have
studied the pharmacokinetics (PK) of both midazolam and its active l-hydroxy metabolite and …

Whether age and sex influence the depth of sedation and the pharmacokinetics of
midazolam is currently unknown. The influence of age and sex was investigated in 117 …

The aim of the study was to study a possible pharmacokinetic-pharmacodynamic (PK-PD)
relationship for midazolam in pediatric intensive care patients and to determine how …

Background Because information on the optimal dose of midazolam for sedation of
nonventilated infants after major surgery is scant, a population pharmacokinetic and …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …

Conclusions The pharmacokinetics of midazolam in our patients showed a shorter half-life,
probably due to the higher hepatic clearance based on the high CI in children, as …

Objectives: To compare the pharmacokinetics and pharmacodynamics of IV midazolam after
cardiac surgery between children with and without Down syndrome. Design: Prospective …

Interventions The pharmacokinetics of midazolam and metabolites were determined during
and after a continuous infusion of midazolam (0.05–0.4 mg/kg/hr) for 3.8 hrs to 25 days …

Midazolam is frequently used to produce sedation in critically ill pediatric patients. We
studied the pharmacokinetics of midazolam in 22 patients (age 8 days to 16 years). The …